Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 7;4(6):1-7.
doi: 10.1093/ehjcr/ytaa320. eCollection 2020 Dec.

Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series

Sarah Blissett  1   2 , David Blusztein  1 , Vaikom S Mahadevan  1
Affiliations

Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series

Sarah Blissett et al. Eur Heart J Case Rep. .

Abstract

Background: There are significant risks of parenteral prostacyclin use in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), which may limit their use. Selexipag is an oral, selective prostacyclin analogue that has been shown to reduce disease progression and improve exercise capacity in patients with PAH-CHD. Administering Selexipag in patients with PAH-CHD could potentially overcome some of the risks of parenteral therapy while improving clinical outcomes.

Case summary: We report five cases highlighting the clinical uses of Selexipag in patients with PAH-CHD. In the first two cases, Selexipag was initiated as part of a Treat-to-close strategy. In the third case, initiation of Selexipag improved symptoms and objective exercise capacity in a patient with Eisenmenger syndrome. In the fourth and fifth cases, rapid cross-titration protocols were used to transition from parenteral prostacyclins to Selexipag. In the fourth case, Selexipag was initiated in the context of significant side effects limiting parenteral prostacyclin use. In the fifth case, Selexipag was used to down-titrate from parenteral prostacyclins following closure of a sinus venosus atrial septal defect and redirection of anomalous pulmonary veins.

Discussion: Selexipag is a promising oral therapy for patients with at various stages of the spectrum of PAH-CHD to improve symptoms, exercise capacity and, in some cases, haemodynamics. Our cases also highlight practical aspects of Selexipag use including targeting the individualized maximally tolerated dose for each patient, managing side effects and managing dose interruptions.

Keywords: Case series; Congenital heart disease; Prostacyclin analogues; Pulmonary arterial hypertension.

PubMed Disclaimer

References

    1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023–1030. - PubMed
    1. Jansa P, Jarkovsky J, Al-Hiti H, Popelova J, Ambroz D, Zatocil T. et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med 2014;14:45. - PMC - PubMed
    1. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S. et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs 2008;68:1049–1066. - PubMed
    1. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed) 2016;69:177. - PubMed
    1. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–804. - PubMed

LinkOut - more resources